SCHEMBL1386958

SCHEMBL1386958

OCCCn1cc2c(-c3cccc(O)c3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.42
CSNK1D P48730 5/20 0.41
CSNK1A1 P48729 3/20 0.41
MAP4K4 O95819 1/20 0.41
MAPK9 P45984 1/20 0.41
CDC42BPA Q5VT25 1/20 0.41
AURKB Q96GD4 1/20 0.41
MAP4K5 Q9Y4K4 1/20 0.41
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
CSNK1E P49674 2/20 0.37
BRAF P15056 1/20 0.37
MAPK3 P27361 1/20 0.37
MAPK1 P28482 1/20 0.37
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384559 0.91 MAPK14 (0.46) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL2929628 0.91 MAPK14 (0.49) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL1386354 0.86 PDE10A (0.39) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL29332356 0.86 MAPK14 (0.48) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL1385083 0.85 MAPK14 (0.46) MAPK14CSNK1DCSNK1A1HSD17B1HSD17B2
SCHEMBL1387083 0.84 MAP4K4 (0.46) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL1383998 0.84 MAPK14 (0.47) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL1386704 0.82 PDE10A (0.46)
SCHEMBL1386148 0.82 ADORA3 (0.49) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9
SCHEMBL1384398 0.82 CSNK1D (0.43) MAPK14CSNK1DCSNK1A1MAP4K4MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885CSNK1D 75/4885CSNK1A1 80/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885CSNK1D 60/4885CSNK1A1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.